Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jun;14(6):741-743.
doi: 10.1111/jdi.13994. Epub 2023 Feb 17.

Commentary on glucose reduction in type 2 diabetes (GRADE)

Yi-Hong Lee  1 , Yuh-Shiou Gu  2 , Yi-Der Jiang  1
Affiliations
Comment

Commentary on glucose reduction in type 2 diabetes (GRADE)

Yi-Hong Lee et al. J Diabetes Investig. 2023 Jun.
No abstract available

PubMed Disclaimer

Comment on

  • Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Butera NM, Cohen RM, Crandall JP, Kahn SE, Krause-Steinrauf H, Larkin ME, Rasouli N, Tiktin M, Wexler DJ, Younes N. GRADE Study Research Group, et al. N Engl J Med. 2022 Sep 22;387(12):1063-1074. doi: 10.1056/NEJMoa2200433. N Engl J Med. 2022. PMID: 36129996 Free PMC article. Clinical Trial.
  • Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    GRADE Study Research Group; Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, Fortmann SP, Green JB, Kahn SE, Kirkman MS, Krause-Steinrauf H, Larkin ME, Phillips LS, Pop-Busui R, Steffes M, Tiktin M, Tripputi M, Wexler DJ, Younes N. GRADE Study Research Group, et al. N Engl J Med. 2022 Sep 22;387(12):1075-1088. doi: 10.1056/NEJMoa2200436. N Engl J Med. 2022. PMID: 36129997 Free PMC article. Clinical Trial.

References

    1. Nathan DM, Lachin JM, Balasubramanyam A, et al. Glycemia reduction in type 2 diabetes – glycemic outcomes: a multicenter, parallel‐group, comparative‐effectiveness clinical trial. N Engl J Med 2022; 387: 1063–1074. - PMC - PubMed
    1. Nathan DM, Lachin JM, Bebu I, et al. Glycemia reduction in type 2 diabetes – microvascular and cardiovascular outcomes: a multicenter, parallel‐group, comparative‐effectiveness clinical trial. N Engl J Med 2022; 387: 1075–1088. - PMC - PubMed
    1. Marso SP, Daniels GH, Brown‐Frandsen K, et al. LEADER Steering Committee, LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes: a multicenter, double‐blind, placebo‐controlled trial. N Engl J Med 2016; 375: 311–322. - PMC - PubMed
    1. Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon‐like peptide‐1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta‐analysis. Diabetes Technol Ther 2015; 17: 35–42. - PMC - PubMed
    1. Zang L, Liu Y, Geng J, et al. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26‐week, open‐label, randomized, active comparator clinical trial. Diabetes Obes Metab 2016; 18: 803–811. - PMC - PubMed